🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to scientists.

An International Challenge

Gonorrhoea infections are on the rise around the world, with estimates suggesting in excess of 82 million new cases per year. Especially elevated rates are reported in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the context of growing infection rates, the spread of superbugs and the very limited treatment choices presently on offer.”

Public health authorities are deeply concerned about the surge in treatment-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance showed that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US FDA in recent days for combating gonorrhoea. This infection can lead to significant complications, including infertility. Experts hope that specific application of this new drug will help slow the development of resistance.

Gepotidacin, originating from the pharmaceutical company GSK, was also approved in the same week. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to develop it.

“This authorization signifies a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Research Study Results and Global Access

As per data published in a prominent scientific publication, zoliflodacin cured more than 90% of uncomplicated infections. This places it at an equal footing with the existing first-line therapy, which combines a dual-drug approach. The research enrolled hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the authority to license and sell the drug in numerous low-income and middle-income countries.

Doctors on the front lines have voiced positive views. The availability of a single-dose, oral treatment like this is seen as a "critical tool" for managing the epidemic. This is viewed as crucial to alleviate the strain of the disease for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.